To present an institutional experience with the use of right liver grafts in adult patients and to assess the practicability and efficacy of this procedure by analyzing the results. Summary Background Data: Living donor liver transplantation (LDLT) for the pediatric population has gained worldwide acceptance. In the past few years, LDLT has also become feasible for adult patients due to technical evolution in hepatobiliary surgery and increased experience with reduced-size and split-liver transplants. Nevertheless, some graft losses remain unexplained and are possibly due to unrecognized venous outflow problems. Methods: From April 1998 to September 2002, we performed 74 right LDLTs (segments 5-8). The 74 donors were selected from 474 candidates according to standard protocol. The median age of the donors was 35 years (range 18 -58 years) and 51 years (range 18 -64 years) in recipients. Standard and extended indications for transplantation were considered. Over the period reported, technical modifications in the bile duct anastomosis (duct-to-duct, end-to-end, or end-to-side) and a new graft implantation technique that provides maximized venous outflow, leading to outcome improvement, were developed. Results: 64.9% of patients had liver cirrhosis and 35.1% had malignancy. While 44 donors (59.5%) presented an uneventful postoperative course, 27% minor (pleural effusion, pneumonia, venous thrombosis, wound infection, incisional hernia) and 13.5% major (biliary leakage, death of a donor due to unrecognized hereditary liver disease, and consecutive liver insufficiency) complications were documented. In recipients, 23% biliary complications and 6.8% hepatic artery thrombosis occurred. The overall patient and graft survival rate after 1 year was 79.4% and 75.3%, respectively. In cases with extended indication, the patient survival rate was 74% and the graft survival rate 68% at 12 months. Using technical modifications in the last 10 recipients, including 2 critically decompensated cirrhotics, the survival rate was 100% at a median follow-up of 3.5 months. Conclusions: In our transplant program, living donor liver transplantation has become a standard option in the adult patient population. The critical issue of this procedure is donor morbidity. Technical improvements in the harvesting and implantation of right grafts can also offer hope to patients with challenging forms of end-stage liver disease or malignant liver tumors.
S ignificant shortage of cadaveric organ donors associated with exponential growth of the number of patients on the waiting list worldwide and the success of living donor liver transplantation (LDLT) in pediatric recipients has forced the medical community to extend this technique to the adult patient population. Although initially met with strong reluctance, liver transplantation from living donors rapidly evolved to a widely adopted technique, since its introduction in a pediatric program by Broelsch et al in 1989, 1 particularly in countries where cadaveric organ donation is not established as a standard procedure due to religious beliefs. Over the past 10 years, more than 2000 LDLTs have been carried out worldwide. In 2001, in Europe and in the United States, 6.9% and 10%, respectively, of all liver transplantations accounted for living donor operations, more than 75% of them performed between genetically related individuals. 2, 3 The application of living donation is associated with several theoretical advantages for the recipient. Surgery can be carried out in a timely fashion when clinically necessary. The quality of the graft is superior to the one harvested from a brain-death donor. Additionally, LDLT offers the possibility of liver replacement to selected patients who may be ineligible for cadaveric organ transplantation. In contrast, LDLT harbors potential risk to a donor, either in terms of direct postoperative morbidity and mortality, or as a negative impact on the long-term quality of life. Donor management has been considered the most important issue of living donation. It has been demonstrated that the risk to the donor can be minimized following current guidelines for LDLT and ethical considerations voiced by the medical community. 4 -6 However, particularly in the situation of extended indication for transplantation, one has to weigh the benefit to the recipient and the possible harm to a healthy individual who serves as a donor. Besides ethical reasons, minimizing the potential causes of donor morbidity is a prerequisite for further progress and acceptance of living donor transplantation.
The success of LDLT, particularly in critical settings, as in decompensated cirrhotics, or tumor patients with poor access to retransplantation shall rely upon excellent technique to prevent programmed failures. The recognition of graft failures of unclear etiology in some of the first 64 recipients led us to the recognition of venous outflow impairment as possibly responsible for phenomena ranging from sustained early dysfunction to graft or patient loss. A new technique aiming to maximize the venous outflow of the right liver graft and resulting in outcome improvement was devised and used in the last 10 cases. This study outlines the general experiences of our group in LDLT in adult recipients and focuses on the most critical problems specifically related to right graft transplantation.
PATIENTS AND METHODS

Donor Selection
The primary selection criterion was the informed consent and the willingness of the person to donate. The stepby-step evaluation protocol encompassed a detailed medical and psychosocial history as well as an evaluation of their physical condition. Standard bedside biochemical serum analysis, viral serologies, and ABO blood group typing followed.
In all but one case, ABO-identical or -compatible donors were taken into consideration. Eligible donors proceeded for a computed tomography (CT) 7 or magnetic resonance imaging (MRI) for hepatic volumetry and for anatomic assessment. Initially, our protocol encompassed liver biopsy only when findings that might indicate pathologic liver conditions were disclosed in advance. After the loss of a donor due to congenital lipodystrophy not diagnosed preoperatively, a liver biopsy became a mandatory part of the evaluation. At the same time, the policy of leaving a rest liver volume body weight ratio (RLVBWR) of 0.8 or 0.7 in donors with normal liver histology was instituted. The donors were requested to auto-donate 2 blood units before surgery. A thorough informed consent process consisting of several interdisciplinary interviews was formalized before the operation. During the interviews morbidity and mortality risks were intensively discussed. Donors and the families were not only informed about their own risks but also on the prognosis of the recipient. Each accepted donor was reviewed by the regional ethical committee. Donor demographics, relationship to the recipient, surgical details, postoperative biochemical profiles, complications, and outcome were analyzed.
Donor Operation
A right hepatectomy, comprising segments 5 to 8, without inflow occlusion, was performed in all cases. A cell saver was routinely used. A cholecystectomy was followed by the isolation of the right hepatic artery and portal vein up to the respective main bifurcation. The right liver lobe was mobilized, and the retrohepatic veins were either ligated or resected with a small cuff for future reimplantation. The retrohepatic dissection encompassed two thirds of the right cava. The caudate process was divided before detaching the hilar plate and before dividing the bile duct. In cases of irregular bile duct anatomy, the common bile duct was accessed with a probe through the cystic duct or via a minimal choledochotomy. The right bile duct(s) were divided sharply. A groove on the posterior face of the liver from the division of the caudate process to the medial margin of the right hepatic vein (RHV) delineated the posterior line of resection. The resection line followed the line of Cantlie as defined by the demarcation of a right hemi-Pringle maneuver and by an ultrasound identifying the middle hepatic vein (MHV). The parenchymal trans-section was done by the Selector ultrasonic dissector (Erbe GmbH, Erlangen, Germany) and electrocautery. A mersilene band passed behind the liver enabled one to guide the resection for the final part of the operation. The resection line was kept along the margin of the MHV. Initially, the MHV was left with the donor. Subsequently, it was resected with the graft in selected cases, provided donors could retain sufficient liver mass. The major vein tributaries of the MHV were identified, resected at the junction with the MHV and preserved for possible anastomoses. After removal, the graft was flushed with cold University of Wisconsin solution (Du Pont Pharma GmbH, München, Germany) or with Histidine-Triptophane-Ketoglutarate solution (Köhler Chemie GmbH, Alsbach-Hänlein, Germany). In cases of recipients with extended tumor, the transplantation was usually performed in a delayed sequence, starting with the recipient procedure, before proceeding to the donor.
Recipients
The evaluation of potential recipients for living donor liver transplantation (LDLT) was the same as for the cadaveric procedure. All recipients for liver transplantation were Eurotransplant (ET) status T2 to T4, comparable to United Network for Organ Sharing (UNOS) status 2a to 4. Besides standard indications for liver transplantation, recipients with extended indications were considered. Extended indications met the following preoperative criteria: 1) acute decompensation of advanced chronic liver cirrhosis (ET status T2), for patients who most likely would not survive the waiting time for a cadaveric organ; and 2) advanced hepatocellular carcinoma (HCC) with Union International against Cancer (UICC) stage IIIA.
The indication for transplantation was liver cirrhosis in 64.9% and tumor disease in 35.1% (Table 1 ). Eight patients with advanced HCC received tumor-specific treatment (hepatectomy, chemoembolization, alcohol injection, radiofrequency ablation) 4 months to 6 years prior to transplantation. Compensated renal failure was present in 30% of the recipients already preoperatively. One patient was on hemodialysis for chronic renal failure prior to liver transplantation and underwent subsequent living donor kidney transplantation. Two recipients presented a severe hepatopulmonary syndrome, in one of them associated with a Berardinelli-Seiplike syndrome.
Recipient Operation
The vena cava was preserved in all cases with the exception of 2 patients with advanced HCC and carcinoid, respectively, in whom the vena cava was resected because of contiguity. In these cases, a homologous aortic cadaveric graft was interposed between the suprarenal and the suprahepatic vena cava. A temporary portocaval shunt was selectively used. The indication was severe portal hypertension, especially in patients with previous abdominal surgery and long anhepatic period to avoid a decrease of body temperature and coagulopathy. The RHV was anastomosed to the cava, directly at the site of the RHV or to custom-enlarged orifices at this same site. Posterolateral sectorial veins were drained directly into the vena cava; anteromedial sectorial veins were initially selectively anastomosed to the middle or left hepatic veins or to both using cadaveric arterial or venous homologous conduits. To maximize venous outflow, predominantly of the anteromedial sector, in the last 10 cases a full drainage of the graft was provided reconnecting all major veins draining the graft. In particular, a single common confluence was created, anastomosing the MHV (Fig. 1A ) or all anteromedial sectorial veins (Fig. 2) to a large triangular caval orifice obtained joining the three hepatic veins ( Fig.  1B) . Hepatic or portal vein homografts or iliac vein allografts (Figs. 1, 2) were used for this purpose. The allografts were obtained from cadaveric donors during multiorgan harvest operations and preserved in University of Wisconsin solution under sterile conditions in a refrigerator at 2°C to 4°C. The grafts used as outflow conduits were blood group identical.
The graft portal vein was mostly anastomosed to the main portal vein of the recipient; in the presence of multiple branches of the right portal vein, a single anastomosis using a common patch was favored. In the majority of cases, the graft hepatic artery was anastomosed to the proper, right or left hepatic artery. The bile duct(s) were reconstructed either with a Roux-en-Y loop or using end-to-end or end-to-side direct anastomosis with T-tube drainage. 
Postoperative Management and Follow-up
All donors were routinely observed in the intensive care unit for 24 hours. The postoperative management included high-dose low-molecular heparin and daily laboratory tests for the whole hospital stay, abdominal-hepatic ultrasound 3 times during the first 24 hours, and then daily for 5 days or as required by the clinic, mobilization within 24 hours from the operation. The donors had follow-up visits in our outpatient clinic 3, 6, and 12 months postoperatively. In recipients, percutaneous Doppler ultrasound examination was performed twice daily during the first postoperative week. Immunosuppression consisted of a quadruple regimen of cyclosporine A, mycophenolate mofetil, basiliximab, and steroids for the first 22 patients. Subsequently, the standard immunosuppression was cyclosporine A, mycophenolate mofetil, and steroids. The 3 patients with sclerosing cholangitis received tacrolimus, mycophenolate mofetil, and steroids. The acute cellular rejection episodes were treated with steroids. Persistent acute rejections were coped with a switch to tacrolimus.
"Learning Curve" and Innovative Venous Outflow Reconstruction
In our LDLT program, over the reported period, a "learning curve" was observed. Modifications regarded mainly the selection process of donors and the surgical techniques both in the donor and recipient.
The main goal of the evaluation of donors was to minimize the risks of the procedure, but also to provide grafts of better quality for the recipients. With this aim two important modifications were introduced in the evaluation protocol of the donors: routine use of the all-in-one CT 7 and routine preoperative liver biopsy.
Concerning the operative technique in donors, the main features were refinements in the dissection and division of the bile duct and refinements in the parenchymal dissection using the ultrasonic device. An understanding of the intraoperative anatomy and the recognition of important intrahepatic structures, particularly the hepatic veins, by means of the ultrasound resulted in a diminution of blood loss, at the expense of the donor operative time ( Table 2 ). Finally, in recipients we developed technical modifications in the bile duct anastomosis 8 and a new implantation technique that provides maximized venous outflow of the graft.
In our initial experience some graft failures of unclear etiology were observed. The clinical picture was characterized by the absence of overt technical complications, renal failure, severe encephalopathy or coma, and progressive or sustained cholestasis. In 5 patients there was partial or complete medial sectorial demarcation, and in 2 cases a capsular liver rupture was found at exploration. In all these 7 cases a suspicion of venous occlusion syndrome was raised, despite ultrasound findings of slow, patent RHV with a pattern changing from a triphasic to a mono-biphasic signal. All these grafts were lost. The pathophysiology of the graft loss was, in our opinion, correlated with the insufficient drainage provided not only by the venous grafts draining the medial right sector, when present, but also by the RHV itself. We observed that the rapid regeneration of the graft in the first 10 posttransplant days was displacing the graft medially and could cause kinking, torsion, or compression-occlusion of the outflow tract(s).
For this reason, we devised a modification of the outflow tract aiming to enlarge the caval orifice and to avoid "choking" of the graft. This was achieved by completely opening the subdiaphragmatic cava joining the triangulation of the three hepatic veins under total caval clamping ( Fig.  1B) . Furthermore, additional outflow tissue between the RHV and the right side of the caval orifice was provided to allow the medial shift of the graft and without obstructing the orifice of the RHV and/or of the grafts draining the medial sector. In addition, a single outflow of either the reconstructed RHV and medial sectorial veins (in grafts without the MHV) or of the RHV and MHV together (in grafts with the MHV) avoided the obstruction caused by the medial shift of the graft secondary to the rapid volume increase in the early postoperative period. Improvement in those three areas has led to better results in recipients.
Data Analysis
Survival analysis was performed using the Kaplan-Meier method. JMP Discovery Software (Cary, NC, USA) was used. 
RESULTS
From
Donor Management and Complications
A total of 195 potential donors were excluded on initial screening because of cardiopulmonary disease, obesity (body mass index Ͼ30) or age (Ͼ65 years). In 110 individuals blood group incompatibility or abnormal viral hepatitis serology accounted for exclusion criteria (step 1). Two antihepatitis B core (anti-HBc)-positive donors were accepted. Finally, 95 potential donors were excluded because of inadequate liver volumetry, psychosocial contraindications, or pathologic liver histology (steps 2-4). The median age of donors accepted was 35 years (range 18 -58 years). Sixteen of 74 (21.6%) donors operated on were not related; 9 of them were spouses. Only one ABO-incompatible potential donor was considered for operation.
Findings during the donor operation never constituted a contraindication to the harvesting of the graft. An explorative laparotomy of the recipient before the donation occurred in 8% of the cases. In 3 cases, the donor operation was aborted because of complications that occurred during the surgery of the recipients. These complications were cardiovascular decompensation in carcinoid syndrome, also known as "carcinoid heart disease" in 2 cases and an acute pulmonary embolism with right heart failure in one case. The respective donors had a partial parenchymal transection in one case, a complete parenchymal transection in a second case, and in the third donor the graft had been just explanted and it could not be used further. The transplant could not be performed in any of these 3 cases, and all patients eventually died within 24 hours. All 3 donors, including the one who underwent the hepatectomy, are alive and active at work doing well.
The mean bilirubin peak was 4.78 Ϯ 3.1 mg/dL. Four donors (5.4%) had fully reversible hyperbilirubinemia (bilirubin Ͼ5 mg/dL, 1 week postoperatively). One donor had a reversible liver insufficiency after a 76% hepatectomy because of underestimation in the preoperative volumetry.
The average hospital stay was 13.3 Ϯ 3.8 days. Overall, 44 of 74 donors (59.5%) had a postoperative course free of complications. Major or minor complications that occurred in the remaining 30 donors are summarized in Table 3 .
One donor died 4 weeks after hepatectomy free of any surgical complications. He was a 38-year-old father of an 18-year-old recipient with Berardinelli-Seip syndrome who himself presented no signs of lipodystrophy or any pathologic laboratory findings. His body mass index was 24.7 and the RLBWR was 0.925. Postoperatively, he developed progressive liver insufficiency and was himself high-urgency listed for cadaveric liver transplantation. He died during a technically uncomplicated transplantation attempt due to acute cardiac failure.
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Recipients
The median age of all recipients was 51 years (range 18 -64 years) and the weight 71 kg (range 45-107 kg). The majority of patients were blood group identical (74.3%). Blood group B patients received identical grafts in only 54% of the cases, due to the rarity of the donors in this group and the severity of the condition of the recipients. In total, 10 patients (7.4%) had a Child-Pugh class A; 9 of them also either had tumors or metabolic disease. Twenty-eight recip-ients (37.8%) fulfilled the criteria of extended indication. In this group, 8 patients had a decompensated end-stage cirrhosis with a mean Model for End Stage Liver Disease score of 31.7. Additionally, 2 of them had HCC. In the HCC group, the criteria exceeding classic indications were multilocularity (9 patients with more than 4 tumors), a single tumor with diameter Ͼ5 cm (4 patients), and 2 tumors with size Ͼ3 cm (1 patient). A major invasion of segmental or portal veins detected at histologic examination (segmental or portal veins) was present in 2 patients. Three of the recipients with extended indication for HCC had undergone previous liver resection, and in 9 patients chemoembolization or thermoablation was previously carried out.
The cytolytic indices of the transplanted grafts peaked on postoperative days 2 or 3 and returned to normal values after 10 days. The peak levels were low, with a mean of 253 Ϯ 46 IU for aspartate aminotransferase and 387 Ϯ 55 IU for alanine aminotransferase. The mean total bilirubin peaked on the second postoperative day to 4.7 Ϯ 0.3 mg/dL and dropped to 2.4 Ϯ 1.0 mg/dL after 4 weeks. Prothrombin time and platelet count recuperated after 1 week (data not shown).
Immunosuppression and Rejection
Acute cellular rejection occurred in 14.8% of patients. The rejection episodes were mostly mild to moderate and were treated successfully with steroids. In 4 patients, a switch to tacrolimus was performed due to persistent rejection.
Complications
Twenty-five patients had major surgical complications as listed in Table 4 . Three patients (4%) suffered serious cardiac complications. In one, an infarction of the papillary Was treated conservatively and recovered uneventfully Wound infection (n ϭ 10) All were treated conservatively and recovered uneventfully Incisional hernia (n ϭ 2)
All were surgically managed and recovered uneventfully muscles caused sudden death. The patient was a 64-year-old woman who also presented unexplained postoperative renal insufficiency. Two other patients had multiple episodes of cardiac arrhythmia. The incidence of renal failure requiring dialysis was 24%.
Mortality and Graft Loss
The overall 1-year patient and graft survival rate was 79.4% and 75.3, respectively. The survival rate of chronic decompensated patients (n ϭ 8) was 66%. The overall 3-year patient and graft survival was 71.0% and 64.3%, respectively, at the mean follow-up of 614 days (range 7-1545 days) ( Figs.  3, 4) .
A tumor recurrence occurred in 3 patients with HCC, 12, 27, and 36 months posttransplantation, respectively. The sites of recurrence were adrenal gland, lung, and bone in one patient, liver and lung in one patient, and lung only in one patient. Patients with extended indications for LDLT showed only slightly worse patient and graft survivals than the group with standard indications ( Table 5) .
Retransplantation was performed in 11 patients (14.9%); 3 of them had an extended indication. Of the latter, 75% are currently alive and doing well. Primary hepatic artery thrombosis or portal vein thrombosis contributed to graft loss in 6 patients. All patients were retransplanted; of them, one died of sepsis. Four of 5 patients with a graft failure of unclear reason and one with a late hepatitis C underwent retransplantation. Neither the early nor the late complications due to biliary anastomotic strictures or leaks determined a graft loss. The bile leaks, however, contributed to decompensation and death of 3 critically advanced cirrhotic patients. After the introduction of the new venous reconstruction technique, the graft and patient survival rate was 100% at a median follow-up of 3.5 months (Figs. 5, 6 ). Only 1 of 10 patients died in the presence of good graft function due to leukoencephalopathy probably attributed to calcineurin inhibitors and pneumonia 4 months after LDLT.
Graft/Recipient Body Weight Ratio
The donor/recipient body weight ratio and graft body weight ratio (GBWR) were 1.06 Ϯ 0.26 and 1.27 Ϯ 0.28 (0.75-2.01), respectively. The mean graft volume was 852.8 Ϯ 135 mL.
Surgical Management: Donor and Recipient
In accordance to our recent technical development, the MHV was resected in 4 of the last 10 donors. The mean blood loss in the donor operation, defined as blood volume transfused, was 471 Ϯ 221 mL; however, in the last 10 cases, it could be reduced to 106 Ϯ 114 mL.
In recipients, a temporary portocaval bypass was used in 54 operations (73%) and simple vessel clamping in the remaining 20 cases. A simultaneous arterial and portal vein reperfusion occurred in 37 cases. The portal vein was reperfused before the artery and the artery before the portal vein in 28 and in 9 cases, respectively. The graft artery was anastomosed in 2 cases to the aorta. In 11 grafts, there were multiple right portal vein branches (2 in 8 cases, 3 in 3 cases). A single cuff was used in 64% of the cases. Besides the RHV, a median of 3 (range 1-4) hepatic veins per graft were anastomosed in the first 64 recipients, before modification of the 
DISCUSSION
Although cadaver donor organs predominate in liver transplantation, the shortage of cadaveric organs forced surgeons to implement surgical innovations, including LDLT. 9, 10 To date, the mortality rate for adult patients on the waiting list for liver transplantation in our region is about 27% and does not show consistent improvement. In addition, 60.2% of T2 recipients listed with Eurotransplant die within 2 months (personal communication, T. Gerling, Eurotransplant Liver Allocation Committee, 2002).
The undisputed disadvantage of this technique is the potential risk of serious complications or death in the donor and a greater incidence of technical complications in recipients. [11] [12] [13] Mortality in living donors represents the gravest complication that can occur. 14, 15 Ethical concerns have been raised, and the success of this procedure will depend ultimately on two critical issues: safety and efficiency of the procedure. This means that donor morbidity and mortality should be reduced to a minimum and that graft and recipient survival rates should be similar to that of conventional liver transplantation. The safety of the donor undergoing a right hepatectomy is primarily achieved with a thorough workup to exclude upfront overt risks. 16, 17 This philosophy translates into several guidelines, which have changed after the loss of a donor in our LDLT program for adults. The donor had an unknown autosomal recessive lipodystrophy syndrome (Berardinelli-Seip syndrome), which is characterized, among other things, by insulin-resistant glucose intolerance, acanthosis nigricans, and hepatic steatosis. There is experimental evidence that regeneration is impaired in the steatotic liver, and the simple subtraction equation 18 does not seem to be adequate to calculate the risk and to predict the rate of liver regeneration.
This fatality prompted us to perform a mandatory liver biopsy in all selected final donors, to precisely evaluate the quality of the liver tissue, thus allowing the computation of the functional rest liver volume. Despite the occurrence of a liver injury in two potential donors, we consider the moderate morbidity of the liver biopsy justifiable compared with the potentially devastating sequelae of liver failure in donors and recipients.
Before the fatal donor incident 6 donors in this series reached a RLVBWR Ͻ0.6. They all recovered from surgery and are currently doing well. Their low rest liver volume was not intentionally set so low, but similarly to others 19 it was the result of a miscalculation of the total liver volume. We switched the focus of the donor selection from the quantity of liver needed in recipients (ie, the GBWR) to the functional reserve of the donors after hepatectomy (ie, the RLVBWR). As a consequence, we introduced the limitation of the RLVBWR to 0.8, a standard liver volume equivalent to Ͼ50% of the theoretical liver volume. Uemoto and the group of Kyoto 19 determined that low liver volume and age Ͼ50 years were factors leading to rest liver dysfunction. Our RLVBWR limits may seem zealous, but they guarantee a sufficient safety margin for donors undergoing this operation, particularly in case of errors in the calculation of liver volume or in case of septic complications.
A differentiate strategy for the sequence of the donorrecipient operations in patients with extended indication has avoided, in our experience, unnecessary laparotomy in 2 donors. In the literature, the rate of aborted donor procedures is described in 5 cases. 4 Marcos reported a survey of the U.S. experience describing a rate as high as 5% (personal communication, National Institutes of Health Meeting, Bethesda, MD, 2000).
Since the waiting time for cadaveric liver transplantation in our region is about 10 months for ET status 3 to 4 and 5 months for ET status 2, we proposed LDLT, particularly to patients with HCC, and also to patients with other malignan- cies. This policy 20, 21 has been harshly criticized, 3,22,23 but there are centers following these guidelines. 24, 25 The fact that 28 recipients died during the pretransplantation workup illustrates the severity of the illness of patients who undergo LDLT at our center. Recipients rejected for the LDLT were basically only candidates with advanced tumor disease, such as HCC in UICC stage IIIB-IIIC-IV or with overt vascular invasion of the main portal vein, or patients with metastatic tumor disease involving the liver.
The overall 1-year patient survival in our series is comparable to that of others. 3, [25] [26] [27] [28] Nevertheless, several other centers seldom select such a wide range of extended indications for liver transplantation. In contrast, many of our recipients were patients that could not receive cadaveric liver transplant because of the severity of their disease and for time limitations. Indeed, the scope of our program is to examine the potential of LDLT in adults, irrespective of the severity of their disease.
Because of the high percentage of recipients with advanced oncologic indication, we expect a higher mortality at a longer follow-up. Considering the patient population that was transplanted, the results are actually surprisingly good. The pretreatment and a relative expeditious transplantation may contribute to the selection of candidates with a better prognosis or with low metastatic potential. Moreover, the quality of life in patients with oncologic disease has been excellent, also with recurrent disease.
Retransplantation was performed because of different technical reasons or because of liver failure due to outflow occlusion. In extended indications, a retransplantation is particularly hard to justify and it should not be performed. However, in our series we broke this principle in three occasions: 1) in one patient, early on when the series was started, 2) in an 18-year-old patient with multifocal HCC, and 3) in a 43-year-old patient with a hemangoendothelioma, a less aggressive malignancy.
Extended indications in our series also show worse patient and graft survivals than the standard group, although not statistically significant ( Table 5 ). Within this group, the advanced cirrhotic patients have a worse short-term outcome. 21, 28 The success of LDLT has been improved by the use of right grafts providing larger volume than left grafts. 29 The transplantation of critical patients such as advanced cirrhotics requires a prompt and sustained liver function. These patients seldom survive graft failures or technical pitfalls. The assumption that the actual graft volume transplanted corresponds to the functional graft volume is almost unanimous. 25 According to the venous occlusion syndrome described above, it seems clear that the graft dysfunction can correspond to the impaired function of some suboptimally drained segments of the graft and that the FGBWR in these patients is reduced. The poorly drained regions correspond to the drainage territory of the MHV, and despite the selective drainage of these vessels some grafts were unfortunately lost.
The group of Hong Kong, who regularly uses the right liver graft with the MHV, never reported such findings. Graft failures of unclear etiology have been described, 25, 30 as well as medial sector congestion, 31 particularly concerning the veins of segments 5 and/or 8. However, other groups that do not routinely implant the veins at the cut section have not reported this clinical picture. Intrahepatic collateral circulation has been described 32 as a delicate rescue mechanism of the obstructed segments.
The innovative technique presented in this paper encompasses a total drainage of the right graft, in particular of the medial sector, into a large common outflow tract not subject to axial twists or functional occlusions. Transplanting grafts with the MHV obviates the medial sectorial outflow impairment, but it can supposedly lead to exposure to increased donor risks. 13, 16 For this reason, we compromised by resecting the MHV in donors only when compatible with our guidelines for RLGBWR. In the other cases, the iliac graft, connected to the major veins of the medial right sector, functions as a substitute for the MHV.
Even though the total drainage might be superfluous 33 and a more selective approach could be implemented, the results presented encourage us to continue studying this technical solution.
patients we are talking about are different: all except 2 who presented directly to us were refused or simply not considered for listing at other centers: these patients are often not even given the chance to enter a liver transplant list. Thus, they have a 100% mortality and in our series they enjoyed a 66% gain in survival, according to the equipoise analysis.
In relation to the death of the donor, it was a catastrophe that was managed with a rescue plan, a plan that every living donor transplantation program should have.
We stopped immediately the activity of the program. And we went to the ethical committee of our institution and put ourselves on probation. We called a meeting with the ethical committee and all the specialties involved in this transplantation program. We examined the case, and there was also a legal investigation after we presented the case to the Public Prosecutor. The case has been already reported at meetings, but it has not been published because that is not possible until the legal investigation is closed.
Within our institution after 3 months of inquiry, after reexamining the whole program, and after delineating the criteria that were just presented, we continued. Recognizing our mistakes we can now provide better right living donor grafts as good alternative options to our patients.
Two months ago we were notified from the Statsanwaltschaft, the German District Attorney of Essen, that the case has been conclusively reviewed and resolved. This case was never openly discussed in public and/or in the press, but only within the professional and medical community in Essen, in Germany, and worldwide. It seems to me that, with a lot of pain and sorrow, the case has been resolved.
